Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for approval of first oral glucagon-like peptide (GLP-1) treatment (semaglutide; Rybelsus) for type 2 diabetes

Positive recommendation is for treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. Rybelsus is first GLP-1 receptor treatment developed for oral use and semaglutide is currently only available as a subcutaneous injection.


European Medicines Agency